Skip to main content

Composition of Medical-Grade Hyaluronic Acid Dermal Fillers (e.g. Juvéderm)

Medical-grade hyaluronic acid (HA) fillers are sterile gels primarily composed of cross-linked hyaluronic acid, formulated with various agents to ensure stability, longevity, and patient comfort. Below is a detailed breakdown of their composition, using Juvéderm (a popular HA filler line) as an example, along with typical percentages or concentrations for each component.

Main Ingredients: Hyaluronic Acid Gel​

Hyaluronic Acid (HA): The chief ingredient in these fillers is non-animal, medical-grade hyaluronic acid – a polysaccharide polymer known for its ability to hold water and add volume. In fillers, the HA is chemically cross-linked to form a gel that resists rapid degradation. The concentration of HA in the gel is high, typically on the order of 15–25 mg per mL (1.5–2.5% by weight) [source] [source]. For example, Juvéderm Ultra contains 24 mg/mL of hyaluronic acid in each syringe [source], and the volumizing filler Juvéderm Voluma contains 20 mg/mL [source]. (By comparison, other brands have similar HA content: Restylane is ~20 mg/mL, Belotero ~22.5 mg/mL [source] [source].) This high HA concentration contributes to the filler’s volumizing effect and thickness (viscosity).

Cross-Linked vs. Non-Cross-Linked HA: In the filler gel, the majority of the HA is cross-linked (chemically bound into a network) to prolong its persistence in tissue. Unmodified (non-cross-linked) HA on its own would be broken down by the body within a day or two [source]. Thus, cross-linking is essential to achieve a longevity of months. Most of the HA in products like Juvéderm is cross-linked into a single-phase, homogeneous gel. However, a small fraction of the HA may be left uncross-linked (free HA) and mixed into the gel. In Juvéderm Ultra/Ultra Plus, a minor percentage of HA remains free – this unmodified HA acts as a lubricant to facilitate smoother injection (reducing extrusion force) [source] [source]. For instance, Juvéderm Ultra Plus is formulated with a slightly higher proportion of cross-linked HA (about 11% more cross-linked content than Ultra) to yield a firmer gel, but both contain some free HA for better flow [source] [source]. In practical terms, the degree of HA cross-linking (often measured as the percentage of HA disaccharide units that are cross-linked) is on the order of a few percent. Juvéderm Ultra is reported to have roughly 6% of its HA units cross-linked, and Ultra Plus about 8% [source]. (Older or softer gels can have lower cross-link densities, e.g. ~1–3% in some formulas [source] [source].) The remaining HA is not chemically bonded, which improves the gel’s malleability and injectability without sacrificing much longevity.

Molecular Weight of HA: The HA used is high molecular weight (typically hundreds of kilodaltons). Newer filler technologies manipulate HA sizes for improved cross-linking efficiency. For example, Juvéderm’s Vycross technology blends 90% low-molecular-weight HA with 10% high-molecular-weight HA before cross-linking [source] [source]. This optimizes the cross-link network, producing a smoother gel that can be more efficiently cross-linked and may last longer. Regardless of molecular weight, the HA is highly purified and derived via bio-fermentation (often from Streptococcus bacterial fermentation) rather than animal sources, to ensure consistency and minimize immunogenic proteins [source] [source]. After production, the HA is in the form of sodium hyaluronate (negatively charged, which helps it bind water and form a gel).

Cross-Linking Agents (BDDE and Others)​

To create a durable gel, the long HA chains are chemically cross-linked using a bifunctional agent. The most common cross-linker in modern HA fillers is 1,4-Butanediol Diglycidyl Ether (BDDE) [source] [source]. BDDE contains reactive epoxy groups that form ether links between HA chains under alkaline conditions [source] [source]. BDDE is preferred due to its efficiency and safety: it forms stable ether bonds that resist enzymatic breakdown (helping the filler last up to 6–12 months in vivo) [source], and it has significantly lower toxicity than older cross-linkers like divinyl sulfone (DVS) [source] [source]. This favorable safety profile and biodegradability have made BDDE the industry-standard cross-linking agent for HA fillers [source] [source]. (Some earlier-generation fillers used other agents: for example, Hylaform (Captique) used divinyl sulfone, and Puragen used 2,7,8-diepoxyoctane (a PEG epoxide) [source]. However, virtually all major HA fillers today (Juvéderm, Restylane, Belotero, etc.) are BDDE-cross-linked.)

[source] Schematic representation of BDDE cross-linking HA. In the cross-linking process, each BDDE molecule (green chain with epoxide rings) can bond to two HA polymer strands, bridging them (A, a “fully reacted” cross-link, shown in red) [source]. Some BDDE may attach to only one HA chain (B, a “pendant” cross-link, blue), leaving the other end of the BDDE unbound [source]. Unreacted BDDE can also simply hydrolyze (C, forming a diol, essentially deactivated) or remain as trace unreacted epoxide (D, “residual crosslinker”) [source] [source]. Manufacturers perform thorough purification after cross-linking to remove these residues. As a result, the final filler gel contains only trace amounts of BDDE: typically <2 ppm (parts per million) of residual BDDE [source] [source]. In real terms, that is less than 0.002 milligram of BDDE per mL of gel – an extremely low level considered safe by regulatory standards [source]. (All FDA-approved HA fillers are required to have <2 ppm unreacted BDDE [source].) The bulk of the BDDE in the product is not free but rather is “locked” into the HA network as ether linkages (either fully cross-linked bridges or pendant side chains), which are themselves biocompatible and break down into innocuous metabolites (BDDE linkages eventually metabolize into glycerol and butanediol in the body over time) [source] [source].

Cross-linker Proportion: During manufacturing, a small proportion of cross-linker is sufficient. Typically, the reaction might use on the order of ~0.5–1% (w/v) BDDE relative to the HA solution to achieve the desired network [source]. This yields a cross-linked HA gel where only a few percent of the HA’s disaccharide units are modified by BDDE (as noted, often ~6–8% in many fillers [source]). The outcome is a gel that is “stabilized” – it resists immediate degradation – yet remains soft enough to integrate into the tissue.

Stabilizers and Preservatives (Buffer, Lidocaine, Antioxidants)​

Aside from HA and crosslinker, the rest of the filler syringe is composed of a physiological carrier solution and minor additives that maintain the gel’s stability and ensure patient comfort. These include:

  • Phosphate-Buffered Solution: The HA gel is suspended in a phosphate buffer (phosphate-buffered saline, PBS) to create a physiological pH and osmotic balance. The buffer typically consists of sodium phosphate salts and sodium chloride, adjusted to about pH 7.0–7.2 [source] [source]. For example, Juvéderm fillers are prepared in a phosphate buffer pH 7.2 (q.s. to 1 mL total volume) [source]. This means the filler gel is carried in a small amount of sterile saline solution that has phosphate ions to maintain a neutral pH, similar to the body’s fluids. The buffer keeps the HA gel isotonic with the body (usually ~0.9% saline equivalent) and ensures that the filler does not cause irritation or dehydration of surrounding cells upon injection [source]. It also helps to stabilize the HA molecules’ structure by providing the right ionic environment. Notably, this solution is not just plain water; the ions (Na⁺, phosphate) prevent the HA from swelling excessively and maintain consistent gel properties. The buffer also acts as a carrier to help the gel flow through the fine needle.

  • Lidocaine (Local Anesthetic): Many modern HA fillers are formulated in an “XC” version that includes lidocaine to reduce injection pain. Lidocaine does not affect the HA’s chemical stability but is a patient comfort additive. Typically, 0.3% lidocaine is incorporated, which is 3 mg of lidocaine per mL of gel [source]. For instance, Juvéderm Ultra XC and Voluma XC each contain 3 mg/mL lidocaine HCl in the final product [source] [source]. This low concentration provides local numbing at the injection site. Lidocaine is added as lidocaine hydrochloride (a salt) which also slightly contributes to the salt content of the buffer. The presence of lidocaine has been shown to significantly reduce pain on injection without altering the filler’s performance [source]. Almost all major fillers offer lidocaine-containing versions (often labeled “with Lidocaine” or “L”). Aside from lidocaine, no other preservatives or bacteriostatic agents (like benzyl alcohol) are usually included, since the product is single-use and sterile. The lidocaine also does not act as a preservative; it’s solely for anesthesia. The filler syringes are sterilized by moist heat (autoclaving) during manufacturing [source] [source], and because they are packaged sterile and intended for one-time use, additional antimicrobial preservatives are not necessary. This yields a product that is sterile, pyrogen-free [source] without needing additives that might affect biocompatibility.

  • Antioxidants: To enhance stability and longevity of the HA, some formulations include antioxidant agents. These compounds scavenge free radicals in the tissue, slowing the oxidative breakdown of HA (since free radical damage can degrade HA gels over time [source]). One common antioxidant excipient is mannitol, a sugar alcohol. Mannitol is used in certain HA filler lines (e.g. Stylage® by Vivacy) as a protective agent. It is typically added in small concentrations (on the order of a few milligrams per mL, roughly 0.5–1% w/v). Mannitol’s role is to neutralize free radicals that are produced in the skin (for example, during inflammation or UV exposure), thereby slowing the degradation of the injected HA [source] [source]. Studies have shown mannitol can prolong the persistence of HA gel in the tissue by reducing oxidative stress on the HA [source] [source]. In addition, mannitol has a slight osmotic effect that may reduce post-injection swelling. Another antioxidant sometimes used is sorbitol (another sugar alcohol) in certain formulations – it serves a similar purpose as mannitol in protecting the HA gel from oxidative damage. It’s important to note that Juvéderm products do not contain mannitol; this additive is seen in other brands (Stylage, and a few others). Juvéderm relies on the robustness of its cross-linking alone for longevity, whereas some competitors include an antioxidant to eke out a longer duration of effect by chemical stabilization [source] [source].

  • Buffer Preservatives: Apart from maintaining pH, the phosphate buffer itself has some stabilizing effect on the HA. No additional preservatives (like parabens or phenol) are present in HA fillers – the manufacturing sterilization and packaging precludes the need for them. The product’s longevity in storage (typically a shelf-life of 1–2 years) is achieved by keeping it in sterile, sealed syringes at room temperature [source] [source], with the buffer preventing any significant hydrolysis of HA during storage.

Other Additives and Enhancers​

Beyond the primary ingredients above, some dermal filler formulations include additional minor components to improve handling, tissue integration, or specific clinical effects. These can include:

  • Glycerol: Glycerol is a humectant (water-binding molecule) that is added to certain HA products, especially those designed for skin hydration or “boosting.” While not common in volumizing fillers like Juvéderm, glycerol is present in products like Restylane Vital and Belotero Revive (which are marketed for improving skin quality). Glycerol can enhance the hydration effect of HA and may slightly prolong the presence of HA by holding water. For example, Belotero Revive contains 17.5 mg/mL of glycerol along with 20 mg/mL HA [source] [source] – roughly a 1.75% concentration of glycerol. The glycerol not only keeps the gel very supple but also provides ongoing moisture to the surrounding tissue. In “skin booster” type HA injections, glycerol (around 16–18 mg/mL) is added to improve the gel’s spread and water retention in the dermis [source] [source]. Glycerol is biocompatible and integrates with the HA matrix without reacting with it (it’s simply mixed in). Its presence can make an HA gel softer and more easily distributed, which is desirable for superficial injections.

  • Mixed Molecular Weight HA: As mentioned earlier, while not an “additive” chemical, some filler lines use a mix of HA chain sizes to tweak the gel’s properties. This Vycross technology (90% low-MW + 10% high-MW) in Juvéderm Voluma/Vollure/Volbella results in a more cross-linkable and smooth gel [source] [source]. The outcome is a highly cross-linked network (Allergan describes it as “highly cross-linked, proprietary” [source]) that still has a low concentration of unbound HA. This improves longevity and cohesivity (the gel holds together as a single mass rather than behaving like discrete particles). Again, this is a formulation strategy rather than a separate ingredient, but it’s worth noting as it enhances the texture and performance of the filler in the skin.

  • Trace Proteins or Impurities: Manufacturers strive to eliminate impurities, but minute traces can remain. For example, HA is produced from bacterial fermentation, so trace residual proteins or DNA from the bacteria (Streptococcus) could be present at extremely low levels. Part of the purification process is aimed at removing these, because residual protein could trigger immune responses. The final HA content in reputable fillers is highly pure, with negligible protein impurities (often below detectable levels), so while not an intentional component, this aspect contributes to biocompatibility. Fillers are also tested to be endotoxin-free and free of microbial contamination. These quality factors ensure the product is biocompatible and safe upon injection, minimizing risks of inflammation beyond the desired effect.

  • Other Novel Additives: A few specialized filler products incorporate additional molecules intended to boost biocompatibility or even bio-stimulation. For instance, some newer formulations include amino acids, vitamins, or minerals in the HA gel (one example is a filler that added calcium hydroxyapatite microspheres to HA, although that is a hybrid and not common in pure HA fillers). However, in mainstream HA fillers like Juvéderm, Restylane, etc., such additives are generally not present. The focus is on pure HA gel quality. One exception is a product that combines HA with lidocaine and buffered tromethamine (in a newer line for skin quality), but these remain niche. The key takeaway is that the standard HA filler composition is quite minimalist: cross-linked HA in a buffered physiological gel, with possibly lidocaine and/or an antioxidant, and not much else.

Concentration Summary: To put the above into perspective with approximate concentrations in a typical 1 mL syringe of an HA filler (like Juvéderm Ultra XC):

  • Hyaluronic Acid: ~20–24 mg (2.0–2.4% w/v) of cross-linked HA gel [source] [source]. This is the active volumizing agent.
  • Cross-linker (BDDE): Only residual traces remain; <0.002 mg (<0.0002% w/v) unreacted BDDE [source]. The amount chemically bound to HA is not reported as free content, but the cross-link density corresponds to only a few percent of HA units modified (e.g. ~6–8% as crosslinks) [source].
  • Uncross-linked HA: A small portion, often around 0.5–1.5 mg (perhaps ~5–10% of total HA) is free HA mixed in, serving to lubricate the gel [source].
  • Lidocaine: 3 mg (0.3% w/v) if the product includes anesthetic [source]. (Lidocaine-free versions have 0%.)
  • Buffer Salts: Phosphate buffer components (e.g., sodium phosphate) and NaCl make up the remainder of the 1 mL (approximately 0.9% NaCl and ~10–20 mM phosphate). This typically accounts for about 970–980 mg of the solution (since the HA and lidocaine together are ~27 mg, the rest ~973 mg is water and salts). For example, a formulation might effectively be “HA 2.4% in buffered saline”. The buffer is q.s. (“quantum satis”) to fill 1 mL volume [source].
  • Antioxidant (if present): e.g. Mannitol ~5–10 mg (0.5–1% w/v) in some products [source], or glycerol ~17 mg (1.7%) in others [source]. In Juvéderm specifically, these are absent; but in Stylage or Belotero Revive, they replace an equivalent volume of the buffer.
  • pH: ~7.0–7.2 (physiologic neutral). Osmolality ~ isotonic (around 300 mOsm/kg, matching body fluids).

In summary, Juvéderm and similar HA fillers are composed chiefly of cross-linked hyaluronic acid (around 20–25% of the content by dry weight, or 2% by volume), a minute amount of cross-linking agent (chemically bound and with <0.0002% residual unbound), and the rest is a sterile aqueous phosphate-buffered carrier. Many formulations include 0.3% lidocaine for pain relief, and some include additives like mannitol or glycerol to enhance the gel’s durability or handling. All components are biocompatible and optimized to ensure the filler is safe, stable, and effective in providing long-lasting tissue augmentation [source] [source].

Sources:

  • Juvéderm product information and FDA filings (ingredient lists and descriptions) [source] [source] [source]
  • Scientific literature on HA filler composition and cross-linking chemistry [source] [source] [source]
  • Reviews on filler rheology and formulation (HA concentrations, cross-link percentages, additives like mannitol/glycerol) [source] [source] [source]
  • Manufacturer and clinical publications on specific additives and technologies (e.g., mannitol in Stylage [source] [source], Vycross HA ratio [source])."